Zenas BioPharma Reports First-Quarter Results and Board Changes

Zenas BioPharma Inc. (ZBIO) on May 13 2026 filed a Form 8-K with the Securities and Exchange Commission that included results of operations and financial condition under Item 2.02, a change in directors and principal officers under Item 5.02, submission of matters to a vote of security holders under Item 5.07, and related exhibits under Item 9.01.

The filing covers the biotechnology company's financial performance for the first quarter of 2026. As a clinical-stage biopharmaceutical company focused on immunology, Zenas BioPharma reports quarterly results that affect its cash position, research and development spending, and runway for ongoing trials of its product candidates.

The exact figures are contained in the exhibits filed with the 8-K.

Under Item 5.02 the company reported both the election of a new board member and the departure of a principal officer. The named individual, role, effective date and any cited cause appear in the filing text. Such officer and director changes require the company to update its governance disclosures and, in the case of executive departures, often prompt a separate Item 5.02 amendment or proxy statement revisions detailing severance, consulting arrangements or equity treatment.

The Item 5.07 section discloses the outcome of shareholder votes, typically covering ratification of auditors, election of directors and any advisory votes on executive compensation. These results set the board's composition for the coming year and confirm shareholder approval of governance actions already taken.

Downstream the filing starts the clock for any required amendments to Form 10-Q or proxy materials. If the departing officer held a Section 16 reporting role, Form 4 filings become due within two business days. The new director must file an initial Form 3 within ten days.

Markets and counterparties in licensing or financing deals receive formal notice of the leadership shift through the 8-K itself.

This 8-K represents the company's first quarterly update since its initial public offering. The combination of financial results, board refresh and shareholder vote outcomes follows standard post-IPO disclosure cadence for a Nasdaq-listed issuer with CIK 0001953926.